This Article Full Text Full Text (PDF) All Versions of this Article: 105/8/999    most recent hc0802.104282v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, H. H. Articles by Burnett, J. C. Search for Related Content PubMed PubMed Citation Articles by Chen, H. H. Articles by Burnett, J. C., Jr Related Collections Heart failure - basic studies

(Circulation. 2002;105:999.)
© 2002 American Heart Association, Inc.

Basic Science Reports

Maximizing the Natriuretic Peptide System in Experimental Heart Failure

Subcutaneous Brain Natriuretic Peptide and Acute Vasopeptidase Inhibition

Horng H. Chen, MB, BCh; John G. Lainchbury, MD; Gail J. Harty, VMT; John C. Burnett, Jr, MD

From the Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Department of Physiology, Mayo Clinic and Foundation, Rochester, Minn.

Correspondence to Horng H. Chen, MB, BCh, Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905. E-mail chen.horng{at}mayo.edu

Background— A hallmark of congestive heart failure (CHF) is the elevation of the cardiac natriuretic peptides (NPs), which have natriuretic, renin-inhibiting, vasodilating, and lusitropic properties. We have reported that chronic subcutaneous (SQ) administration of brain natriuretic peptide (BNP) in experimental CHF improves cardiorenal function. Vasopeptidase inhibitors (VPIs) are single molecules that simultaneously inhibit both neutral endopeptidase 24.1 (NEP) and ACE. We hypothesized that acute VPI administration would potentiate the cardiorenal actions of SQ BNP in experimental CHF.

Methods and Results— We determined the cardiorenal and humoral responses to acute VPI alone with omapatrilat (OMA) (1 µmol/kg IV bolus) (n=6), acute low-dose SQ BNP (5 µg/kg) alone (n=5), acute VPI plus low-dose SQ BNP (n=5), and acute high-dose SQ BNP (25 µg/kg) alone in 4 groups of anesthetized dogs with experimental CHF produced by ventricular pacing for 10 days. Plasma BNP was greater with VPI+low-dose SQ BNP compared with VPI alone or low-dose SQ BNP alone and was similar to high-dose SQ BNP alone. Urinary BNP excretion was greatest with VPI+SQ BNP. Urinary sodium excretion was also highest with VPI+SQ BNP, with the greatest increase in glomerular filtration rate. VPI+SQ BNP resulted in a greater increase in cardiac output and reduction in cardiac filling pressures as compared with low-dose SQ BNP, high-dose SQ BNP, or VPI alone.

Conclusions— This study reports that acute VPI potentiates the cardiorenal actions of SQ BNP in experimental CHF. This study advances the concept that protein therapy with BNP together with vasopeptide inhibition represents a novel therapeutic strategy in CHF to maximize the beneficial properties of the natriuretic peptide system.

Key Words: natriuretic peptides • heart failure • pacing

This article has been cited by other articles:

				O. Lisy, B. K. Huntley, D. J. McCormick, P. A. Kurlansky, and J. C. Burnett Jr Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide: CD-NP. J. Am. Coll. Cardiol., July 1, 2008; 52(1): 60 - 68. [Abstract] [Full Text] [PDF]

				G. W Yip B-type natriuretic peptide: a treatment, not a diagnostic marker Heart, May 1, 2008; 94(5): 542 - 544. [Full Text] [PDF]

				H. H. Chen and J. C. Burnett Jr Clinical application of the natriuretic peptides in heart failure Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E18 - E25. [Abstract] [Full Text] [PDF]

				J. McCord, B. J. Mundy, M. P. Hudson, A. S. Maisel, J. E. Hollander, W. T. Abraham, P. G. Steg, T. Omland, C. W. Knudsen, K. R. Sandberg, et al. Relationship Between Obesity and B-Type Natriuretic Peptide Levels Arch Intern Med, November 8, 2004; 164(20): 2247 - 2252. [Abstract] [Full Text] [PDF]

				M. Pfister, N. E. Martin, L. P. Haskell, and J. S. Barrett Optimizing Dose Selection with Modeling and Simulation: Application to the Vasopeptidase Inhibitor M100240 J. Clin. Pharmacol., June 1, 2004; 44(6): 621 - 631. [Abstract] [Full Text] [PDF]

				U. Alehagen, G. Lindstedt, H. Eriksson, and U. Dahlstrom Utility of the Amino-Terminal Fragment of Pro-Brain Natriuretic Peptide in Plasma for the Evaluation of Cardiac Dysfunction in Elderly Patients in Primary Health Care Clin. Chem., August 1, 2003; 49(8): 1337 - 1346. [Abstract] [Full Text] [PDF]

				H. H. Chen, J. G. Lainchbury, and J. C. Burnett Jr Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1186 - 1191. [Abstract] [Full Text] [PDF]